Skip to content

Shattuck Labs, Inc. STTK Number of Exercisable Options

Number of Exercisable Options at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$7.5M
Immunovant, Inc. logo
Immunovant, Inc.IMVT
5M-45.1%

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s number of exercisable options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s number of exercisable options?
Shattuck Labs, Inc. (STTK) reported number of exercisable options of 5.1M in Q1 2026.
How has Shattuck Labs, Inc.'s number of exercisable options changed year-over-year?
Shattuck Labs, Inc.'s number of exercisable options increased by 43.8% year-over-year, from 3.5M to 5.1M.
What is the long-term trend for Shattuck Labs, Inc.'s number of exercisable options?
Over 5 years (2020 to 2025), Shattuck Labs, Inc.'s number of exercisable options has grown at a 37.9% compound annual growth rate (CAGR), from 868.8K to 4.3M.
What does number of exercisable options mean?
The number of share-based payment options that have met all vesting requirements and are currently eligible for exercise by the holders. This represents the portion of the equity incentive pool that could be converted into common stock immediately. It is a critical component for calculating fully diluted share counts.